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simple risk model could aid in decision-making in the clinic
and highlights areas of potential intervention to reduce NRM
following auto HCT.
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Introduction: Survivors after HCT often have musculoskel-
etal complications and symptoms. Although risk factors for
many of the musculoskeletal complications have been
deﬁned, risk factors for symptoms remain unknown.
Methods: All HCT survivors treated at the Fred Hutchinson
Cancer Research Center and living in zip codes beginning with
98 were approached and asked to complete patient reported
outcomes (PRO) and permit use of their medical records. To
reduce age-related confounding ofmusculoskeletal symptoms
associated with HCT, eligibility criteria included survivors
between ages 18-49, with myeloablative HCT for hematologic
malignancy between 5-20 years before approach and English
proﬁciency adequate to complete the PRO. Exclusion criteria
were relapse or second cancer other than basal or squamous
cell skin cancer within the previous 2 years. We used the
Muscle and Joint Measure (MJM) with subscales to evaluate
outcomes of cramps, arthralgias, myalgias and weakness. Due
to a lack of normative information, we used the mean plus 0.5
SD for each subscale as a cut point to deﬁnepatientswithmore
severe symptoms. Variables signiﬁcant at p<.10 were retained
from univariate regressions, followed by backward elimina-
tion to p<.05 level for the ﬁnal models.
Results: Of 170 eligible participants, 142 completed the PRO
(84%). A majority were male (53%) with mean age 39.5
(SD¼8.9), years post-HCT mean of 11.2 (SD¼4.6); 40%
received related allogeneic HCT, 32% unrelated, 28% autolo-
gous; 65% received TBI, 32% received bone marrow as aTable 1
Final models for multivariate logistic regressions of risk factors for
musculoskeletal symptoms
OR (95% CI) P
Cramps
Age  40 2.45 (1.1-5.5) 0.03
Katz comorbidity  2 2.42 (1.1-5.3) 0.03
Arthritis 6.71 (2.4-18.5) 0.0002
AVN 3.28 (1.2-8.8) 0.02
Arthralgia
GVHD meds now 8.68 (2.1-35.5) 0.003
Age  40 4.44 (1.6-12.2) 0.004
Arthritis 22.3 (6.9-72.7) <0.0001
Myalgia
Katz comorbidity  2 2.27 (1.1-4.8) 0.03
AVN 2.83 (1.1-7.1) 0.03
Weakness
GVHD meds now 12.4 (2.4-63.0) 0.002
AVN 3.09 (1.1-8.4) 0.03
Diabetes 6.71 (1.8-25.2) 0.005source of stem cells. For late effects potentially relevant to
musculoskeletal symptoms, 16% had taken oral immuno-
suppressants for >24 months for chronic graft versus host
disease (cGVHD), 8% were currently taking medication for
cGVHD, 8% were taking diabetes medication, 17% reported
avascular necrosis (AVN), 18% reported arthritis, and 49% had
 2 comorbid conditions. Survivors reporting symptoms of
moderate or greater intensity (>4 on 0-10 scale) and occur-
ring at least weekly were: cramps 30%, myalgias 26%, joints
22%, and weakness 20%. Table 1 deﬁnes risk factors.
Conclusions: Different risk factors predicted each of the
musculoskeletal symptoms in HCT survivors. Further
research is needed to understand mechanisms and treat-
ments for these symptoms, particularly for cramps which are
the most prevalent.LEUKEMIA
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Introduction: Central nervous system (CNS) involvement
in adult acute myeloid leukemia (AML) occurs in 2-4% of
patients at diagnosis, and is considered to have a poor
prognosis. Therefore, CNS involvement in AML is an indi-
cator for allogeneic hematopoietic stem cell transplantation
(allo-HSCT). However, the impact of CNS involvement in
AML on the outcome of allo-HSCT remains unclear. We
performed a large-scale nationwide retrospective analysis
to elucidate the outcomes of allo-HSCT for AML with CNS
involvement.
Methods: Clinical data were collected from a registry
database of the Japan Society for Hematopoietic Cell Trans-
plantation. AML patients with CNS involvement aged
16 years or older who underwent the ﬁrst allo-HSCT between
January 2006 and December 2011were compared to the AML
patients without CNS involvement who underwent the ﬁrst
allo-HSCT in the same period. CNS diseases of these patients
were diagnosed at any time from onset to allo-HSCT. The
clinical factors affecting overall survival (OS) of AML patients
with CNS involvement were analyzed using log-rank test and
Cox proportional hazard model.
Result: There were 157 and 4911 AML patients with
and without CNS involvement, respectively. Clinical
